A valid prescription requires a telehealth consultation with a prescriber. No medication is dispensed without clinical evaluation.
These compounded medications are not FDA-approved and have not undergone FDA review for safety or efficacy. Quality and purity depend on pharmacy practices.
Semaglutide
GLP-1 Receptor Agonist
Compound Specifications
Semaglutide
GLP-1 Receptor Agonist
Semaglutide is a well-studied GLP-1 receptor agonist evaluated in clinical trials for its effects on glycemic response, gastric emptying, and hypothalamic satiety signaling, and is prescribed under medical supervision for weight management.
Selectively activates GLP-1 receptors in the brain and gut, elevating postprandial insulin release while suppressing glucagon secretion. Slows gut motility to promote prolonged fullness.
Prescriber Oversight: All prescriptions are issued only after evaluation by a licensed prescriber determines treatment is appropriate. Results may vary. Individual outcomes depend on adherence, baseline health, and other factors.
Important Safety Information
This medication is available by prescription only and requires evaluation by a licensed provider. It is not appropriate for everyone. Compounded medications are not FDA-approved, and the FDA does not review compounded preparations for safety, effectiveness, or manufacturing quality before they are dispensed.
Tell your provider about all medical conditions, allergies, and medications you take, and whether you are pregnant, planning to become pregnant, or breastfeeding.
Report suspected adverse reactions to your provider and to FDA MedWatch at 1-800-FDA-1088 or fda.gov/medwatch.
Clinical Evidence for Semaglutide
Clinical outcomes described in published studies generally relate to FDA-approved semaglutide products studied under specific protocols. The compounded semaglutide formulation offered through this platform is not FDA-approved and has not been reviewed by FDA for safety, effectiveness, or manufacturing quality.
Results may vary. Individual outcomes depend on adherence, baseline health, and other factors.
Individual results may vary. Clinical outcomes reported in studies may not predict an individual patient's response, and compounded formulations are not FDA-approved.
Administered via weekly subcutaneous injection, titrated under clinical guidance to optimal patient response and tolerance.
Frequently Asked Clinical Questions
How is Semaglutide shipped?
Shipped directly to your doorstep in insulated, temperature-controlled cold packs with tracking.
Where is this medication compounded?
Compounded and shipped from licensed U.S. compounding pharmacies pursuant to a patient-specific prescription.
This compounded semaglutide formulation is not FDA-approved and is prepared by a licensed U.S. compounding pharmacy for an individual patient pursuant to a valid prescription. FDA-approved semaglutide products exist for specific indications; clinical evidence from those approved products should not be interpreted as establishing identical outcomes for this compounded formulation. Individual results vary. This page is for informational purposes only and does not constitute medical advice.
Compounded preparations are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or manufacturing quality. This page is for informational purposes only and does not constitute medical advice.